CD33 CAR-T / Hedy Group, Zhejiang University - LARVOL DELTA

CD33KO-CD33-mesothelin Loop CAR design avoids fratricide and improves efficacy of iNK cells against acute myeloid leukemia. (PubMed, J Immunother Cancer) - "Loop CAR empowered both UCB-NK cells and hPSC-iNK cells with superior cytotoxicity against CD33+MSLN+ tumor cells. Genetic disruption of CD33 avoided fratricide and improved efficacy of Loop CAR-iNK cells against AML. This innovative strategy possesses unique advantages and translational potential for treating AML."

Journal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD33 • MSLN

A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=27 | Recruiting | Sponsor: Zhejiang University

New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells. (PubMed, Cell Oncol (Dordr)) - "Overall, the engineering of a single-vector targeting IL10R CAR, which subsequently secretes CD33-targeted bsAb, addresses the issue of immune escape due to the heterogeneous expression of IL10R and CD33, and represents a promising progress in AML therapy aimed at improving treatment outcomes."

CAR T-Cell Therapy • IO biomarker • Journal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • IL10

Myeloid leukemia-derived galectin-1 downregulates CAR expression to hinder cytotoxicity of CAR T cells. (PubMed, J Transl Med) - "The discovery of the role of galectin-1 in cell surface CAR down-regulation provides important insights for developing strategies to restore anti-tumor functions."

CAR T-Cell Therapy • Journal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD33 • LGALS1

Off-the-Shelf, Multiplexed-Engineered iPSC-Derived CD33 CAR-NK Cells for Treatment of Acute Myeloid Leukemia (ASH 2022) - "Immune cell therapy has become a cornerstone in cancer therapy. When administered in combination with daratumumab, QN-023a demonstrated superior ADCC compared to unmodified iPSC-derived NK cells against primary AML blasts from patients. Together, we have engineered iPSC-derived QN-023a NK cells as promising clinical drug candidates for treatment of AML."

IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Solid Tumor • Transplantation • CD33 • IL15 • NKG2D

Evaluate the Safety and Efficacy of CD33 CAR-T in Patients With R/R AML (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: Zhejiang University

New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD33